ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cayman, MD Anderson In Cancer Drug Pact

by Michael McCoy
September 28, 2015 | APPEARED IN VOLUME 93, ISSUE 38

[+]Enlarge
Credit: MD Anderson
Researchers at MD Anderson’s South Campus labs in Houston.
09338-buscon-researchlabcxd.jpg
Credit: MD Anderson
Researchers at MD Anderson’s South Campus labs in Houston.

Biochemicals supplier Cayman Chemical is joining with the University of Texas MD Anderson Cancer Center and Fannin Innovation Studio to form ACF Pharmaceuticals, a drug company that will pursue small-molecule inhibitors for inflammation-induced cancers such as melanoma and colon cancer. Under the pact, Cayman will develop molecules that modulate the cyclooxygenase (COX) pathway. MD Anderson will evaluate them, and Fannin, a Houston-based life science commercialization firm, will provide funding and management.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment